Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, paliperidone (Invega®) cannot be endorsed for use within NHS Wales for the treatment of schizoaffective disorder in adults. |
||
|
||
Medicine details |
||
| Medicine name | paliperidone (Invega®) | |
| Formulation | 6 mg prolonged-release tablet, 9 mg prolonged-release tablet, 12 mg prolonged-release tablet, 3 mg prolonged-release tablet | |
| Reference number | 2797 | |
| Indication | For the treatment of schizoaffective disorder in adults. |
|
| Company | Janssen-Cilag Ltd | |
| BNF chapter | Central nervous system | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Ratification by Welsh Government | 09/10/2015 | |
| Date of issue | 13/10/2015 | |